What is PODRAS™

PODRAS™ is a proprietary delivery technology to reduce the risk of overdose from solid‑dose medications when more tablets than prescribed are swallowed intact. The system is designed so that if multiple pills are ingested at once, the total amount of active pharmaceutical ingredient (API) released over 24 hours is significantly lower than expected while still ensuring full release when the correct dose is taken as prescribed.

By modulating bioavailability based on the number of tablets taken, PODRAS™ introduces a “paradoxical” release behavior: the more you exceed the prescribed dose, the less active drug is released helping mitigate overdose risk and discourage misuse.

Why PODRAS™ Matters

01

Overdose Risk Reduction

Prevents exaggerated dose‑effect from accidental or intentional overconsumption of intact tablets.

02

Enhanced Safety for Solid Dosage Forms

Provides an added safety layer especially for high-risk medications like extended‑release opioids or other controlled substances.

03

Maintains Intended Therapeutic Effect

When used as directed, the release profile remains as expected, ensuring efficacy without compromising safety.

04

Supports Regulatory & Commercial Needs

Can be applied to branded (novel) and generic products, aligning with evolving safety expectations for oral solid doses.

Typical Use Cases & Therapeutic Areas

PODRAS™ is particularly suitable for:

Safer Opioid Therapy

Extended‑release opioids or analgesics
where overdose or misuse risk is a concern.

Narrow Window Safety

Controlled‑release drugs with narrow
therapeutic windows where dose‑excess could cause toxicity.

At-Home Dose Protection

Solid oral formulations (tablets, capsules) intended for at‑home use where incorrect dosing (accidental or deliberate) may occur.

Overdose-Resistant Design

Products developed under either novel or
generic regulatory pathways, seeking an overdose‑resistant edge.

At Medicap Labs, our PODRAS™ offerings include:

Formulation Development

Custom development of dosage forms with overdose‑resistant release profiles, adjusted per API and therapeutic requirement.

Regulatory Support

Regulatory support for both ANDA (generic) and NDA (505(b)(2) or novel) pathways

Release Customization

Adaptable for various APIs and dose strengths enabling application across a wide range of controlled or high‑risk medications.

Scale-Up

Scale-up and GMP-compliant production capabilities ensuring reliable transition from lab to commercial batches

Interested in exploring how PODRAS™ can meet your development needs? Reach out to our team to discuss your API, target release profile, and regulatory strategy.

Get Started